ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,285.71
1.21%
Dow Jones
40,635.79
1.75%
Gold vs US Dollar
2,384.145
0.84%
Brent Oil
80.375
-1.42%
Bitcoin
67,505.15
2.61%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Milestone Pharmaceuticals Inc (MIST)

  7. Milestone Pharmaceuticals Inc (MIST) News

Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MIST
DateTimeSourceHeadlineSymbolCompany
17/07/202421:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MISTMilestone Pharmaceuticals Inc
17/07/202421:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MISTMilestone Pharmaceuticals Inc
17/07/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MISTMilestone Pharmaceuticals Inc
17/07/202421:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MISTMilestone Pharmaceuticals Inc
16/07/202423:06Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
15/07/202421:41Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:MISTMilestone Pharmaceuticals Inc
15/07/202421:38Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MISTMilestone Pharmaceuticals Inc
15/07/202421:36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MISTMilestone Pharmaceuticals Inc
15/07/202421:34Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MISTMilestone Pharmaceuticals Inc
15/07/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
29/05/202412:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
22/05/202413:00GlobeNewswire Inc.Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT AwarenessNASDAQ:MISTMilestone Pharmaceuticals Inc
13/05/202412:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
13/05/202411:59Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MISTMilestone Pharmaceuticals Inc
04/03/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
01/03/202421:52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MISTMilestone Pharmaceuticals Inc
29/02/202412:00GlobeNewswire Inc.Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
28/02/202421:37GlobeNewswire Inc.Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
26/02/202412:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
15/02/202401:56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
14/02/202412:10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202313:54Dow Jones NewsMilestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDANASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202312:57Dow Jones NewsMilestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File LetterNASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202312:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
21/11/202312:00PR Newswire (US)Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
21/11/202312:00PR Newswire (Canada)Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202312:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202311:57PR Newswire (Canada)Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202311:57PR Newswire (US)Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202311:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIST

Your Recent History

LSE
LLOY
Lloyds Banking
LSE
PPP
Pennpetro Energy
LSE
GDR
Genedrive
LSE
PANR
Pantheon Resources
LSE
UKOG
Uk Oil & Gas
LSE
SOLG
Solgold
LSE
OCDO
Ocado
LSE
SCLP
Scancell
LSE
BIRD
Blackbird
LSE
SBTX
Skinbiotherapeutics
LSE
GWMO
Great Western Mining
LSE
VAST
Vast Resources
LSE
POS
Plexus
LSE
GCM
Gcm Resources
LSE
SYME
Supply@me Capital
LSE
ITM
Itm Power
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved